Diabetes Dialogue: ADCES 2025 Part 3 & Diabetes Tech Updates

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

In this episode, Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, shared highlights on several major insulin delivery updates making waves at recent meetings.

They began with Modular Medical’s Pivot insulin pump, a new tubeless device that delivers both basal and bolus insulin with a 300-unit reservoir. Unlike automated insulin delivery (AID) systems, Pivot offers a simpler design with set basal rates and bolus dosing in fixed increments. Isaacs and Bellini noted it could appeal to people with type 2 diabetes who prefer a straightforward option without CGM integration, though they questioned how broad its market will be as AID systems become standard.

Next, attention turned to Medtronic’s partnership with Abbott and the announcement of the Instinct sensor, a 15-day CGM designed to work seamlessly with Medtronic pumps. The panelists welcomed the prospect of longer wear and tighter pump integration, especially for people who prefer fewer device changes.

The conversation then shifted to Tandem’s new infusion set, which extends wear to 7 days. With multiple side ports to reduce occlusions, a kink-resistant design, and a one-handed insertion system, the set addresses longstanding pain points with infusion sites. Both experts expressed excitement about how this could reduce burden and expand insertion site options for users. Before concluding, hosts highlight Tandem’s plans for a tubeless version of the Mobi pump, pairing its Control-IQ algorithm with a patch-style design.

Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.

References:

1. Innovation Pipeline | Medtronic. Medtronicdiabetes.com. Published June 23, 2020. Accessed August 22, 2025. https://www.medtronicdiabetes.com/about-medtronic-innovation/innovation-pipeline#innovation-timeline
2. Whooley S. Tandem picks up FDA clearance for 7-day infusion set. Drug Delivery Business. Published August 19, 2025. Accessed August 22, 2025. https://www.drugdeliverybusiness.com/tandem-fda-clearance-7-day-infusion-set/